Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus DELALUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus DELALUTIN.
AYGESTIN vs DELALUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Category C
Category C
Progestin
Progestin